Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 293157
The license is to develop and commercialize certain patents in order to develop, manufacture, market, distribute, sell, repair and refurbish products, all within the use of the 2019 Hebrew Licensed Technology for (i) Cannabinoid phenolate metal salts, including mono, di and trivalent metals such as Li, Na, K, Ca, Mg, Zn, Fe and Al and their mixtures with native or synthetic cannabinoids, their pharmaceutical formulations, including for oral and topical administration; and (ii) pharmaceutical formulations, for the administration of cannabinoid chemical derivatives, including any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the â€œ2019 Fieldâ€).
IPSCIO Record ID: 255048
IPSCIO Record ID: 372460
This agreement is for the research and early stage development of pharmaceutical preparations based upon Research Compounds (as defined below) for the treatment of CNS and cancer indications.
Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.
Botanical Drug Candidate or BDC shall mean
— any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
— a combination of two or more Phytocannabinoid extracts described above containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and,
— any biological or chemical modification of the Phytocannabinoids in above including any metabolite or degradant.
Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid) or outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).
Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabiooid but which has been developed with information resulting from the Research Collaboration and for which one or more patent.
Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.
The Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.